Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor

Similar Items

• Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer
  od: Yoon, Seong-Hoon, i dr.
  Izdano: (2015)
• Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
  od: Yoon, Joon‐Young, i dr.
  Izdano: (2019)
• Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
  od: Choi, Hayoung, i dr.
  Izdano: (2015)
• A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
  od: Park, Cheol-Kyu, i dr.
  Izdano: (2021)
• A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
  od: Park, Cheol-Kyu, i dr.
  Izdano: (2019)